Web 3.0 Strategies Capture Public Attention
The strategies and frameworks surrounding Web 3.0 from publicly traded companies have sparked significant public interest. In response to this growing curiosity, ME has initiated the series titled “Executive Interviews with Crypto Concept Stocks.” This series aims to engage with visionary leaders who are at the forefront of digital transformation, delving into their strategic approaches, innovative business models, and financial advancements while offering insightful perspectives for industry stakeholders.
Huajian Medical’s Strategic Partnership Announcement
On August 8, 2025, Huajian Medical IVD MEDICAL (01931.HK), a company listed on the Hong Kong Stock Exchange, made headlines by announcing a major global strategic partnership with HashKey Exchange, the largest licensed platform for virtual asset trading in Hong Kong. The company revealed its procurement of an initial batch of Ethereum (ETH) reserves worth HKD 149.47 million and launched its “Global Enhanced Ethereum ‘ETH’ Treasury” strategy, which includes a mechanism for downward protection.
Exploring the Perception of Conservatism in the Medical Sector
In a recent interview, Gary Deng, the Chief Strategy Officer of Huajian Medical, discussed the balance between the medical industry’s traditionally conservative aspects and the dynamic realm of Web 3.0. He argued that while the medical field has established norms, it also embraces innovation. This sector is characterized by high demand and stringent compliance, with historical breakthroughs driven primarily by scientists. However, the lengthy research and development cycles for new drugs pose challenges, typically requiring substantial investments and nearly a decade for a product to move from the lab to market.
Challenges for Small and Medium-Sized Pharmaceutical Companies
Deng highlighted the difficulties faced by small and medium-sized innovative drug companies, particularly in light of the tightening global financial landscape. Many of these companies possess strong pipeline assets but struggle to meet the listing criteria of the Hong Kong Stock Exchange and Nasdaq, leaving them without access to crucial global capital. Despite the significant interest from large international pharmaceutical firms, such as Pfizer and Merck, the majority of smaller companies find it hard to connect with the global market, underscoring a critical imbalance between supply and demand.
Leveraging Web 3.0 Opportunities in the Pharmaceutical Sector
This gap in the market has led Huajian Medical to recognize the potential for integrating Web 3.0 and blockchain technology into the pharmaceutical industry. Deng explained that Web 3.0 should not be viewed as a competing force but rather as a significant ally that can enhance the global allocation of traditional medical assets, forming the foundation of the company’s strategic vision.
Ethereum ‘ETH’ Treasury Strategy: A New Approach
Currently, Huajian Medical has secured board approval to allocate HKD 880 million for the purchase of Ethereum, having already invested HKD 149.47 million. The company plans to continue increasing its holdings through a systematic investment strategy. Furthermore, they are pursuing a more ambitious plan of HKD 3 billion, which awaits shareholder consent. Uniquely, Huajian Medical’s Ethereum treasury strategy is designed to be “enhanced” rather than merely accumulating digital assets; it integrates with the innovative drug Real-World Asset (RWA) exchange ecosystem.
Choosing Ethereum Over Bitcoin
When asked why Ethereum was chosen over Bitcoin, Deng clarified that Ethereum’s infrastructure, which supports smart contracts, decentralized finance (DeFi), and asset issuance, aligns more effectively with the company’s operational needs. This infrastructure facilitates the tokenization and trading of innovative drug intellectual properties, an area where Bitcoin falls short.
Attracting Stakeholders in the Pharmaceutical Field
A significant challenge remains in drawing healthcare professionals, pharmaceutical scientists, and traditional investors into the blockchain space. Deng outlined key participants in the ivd.xyz exchange ecosystem, including asset issuers—primarily smaller pharmaceutical firms seeking funding through asset tokenization—platform operators like Huajian Medical, compliance service providers, and a diverse range of investors. He emphasized that the primary goal is not to convert every industry professional into a blockchain user but to address their real challenges, such as financing difficulties and low asset liquidity.
Gradual Acceptance of Blockchain Technology
Deng expressed confidence in the gradual acceptance of blockchain technology, noting that the global trend towards digitalization is inevitable. Huajian Medical aims to build trust in the system through compliance and transparency, fostering a more comprehensive understanding of the technology among stakeholders.
Ambitions for Global Expansion
As part of its globalization strategy, Huajian Medical is also actively pursuing a secondary listing in the United States. Deng stated that the company aspires to set a benchmark for Ethereum treasury reserves in Hong Kong and across Asia, gradually establishing a foothold in the global Web 3.0 medical financial ecosystem. The interplay between the medical industry’s stability and the agility of the Web 3.0 landscape is creating a unique strategy for Huajian Medical, potentially leading other traditional industry leaders to reconsider their approach to asset management, liquidity, and global outreach.
Important Reminder for Investors
ChainCatcher urges readers to adopt a rational view of blockchain technology, emphasizing the need for heightened risk awareness and caution regarding various virtual token offerings and speculative ventures. The information shared on this platform serves solely for market insight or opinions from relevant parties and should not be interpreted as investment advice. Should any sensitive content be identified, readers are encouraged to report it for prompt attention.
